| Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents (NCT05346731) | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 2022-04-01 |
| Use of Aromatherapy to Reduce Symptom Burden (NCT05251337) | Indiana University | 2022-03-07 |
| Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC (NCT05199818) | Xiamen LP Pharmaceutical Co., Ltd | 2022-03-01 |
| Anti-emetic Prophylaxis With or Without Dexamethasone (NCT05242874) | Henan Cancer Hospital | 2022-02-01 |
| The Effect of Breathing Exercise on Chemotherapy-induced Nausea and Vomiting in With Autologous Hematopoietic Stem Cell Transplantation Patients (NCT05311371) | Istanbul University - Cerrahpasa | 2022-02-01 |
| Granisetron Transdermal Patch System for Prevention of CINV by CapeOX (NCT05325190) | Tianjin Medical University Cancer Institute and Hospital | 2021-10-10 |
| Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer (NCT05564286) | Shantou University Medical College | 2021-07-01 |
| Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients (NCT04873284) | Shanghai Children's Medical Center | 2021-05-01 |
| Auricular Neurostimulation for Chemotherapy Induced Nausea and Vomiting (NCT05143554) | Medical College of Wisconsin | 2021-04-29 |
| Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk) (NCT04817189) | Helsinn Healthcare SA | 2021-02-01 |
| Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants (NCT04535141) | UNC Lineberger Comprehensive Cancer Center | 2020-08-18 |
| Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting (NCT04085393) | University of Alabama at Birmingham | 2020-08-15 |
| Prevalence of Anticipatory Nausea and Vomiting in Cancer Patients Exposed to Highly Emetogenic Chemotherapy (NCT04785495) | Instituto Brasileiro de Controle do Cancer | 2020-08-12 |
| Prevalence of Delayed Chemotherapy Associated Nausea (NCT04342780) | Antje Koller | 2020-06-29 |
| Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV (NCT04437017) | Fifth Affiliated Hospital, Sun Yat-Sen University | 2020-02-03 |
| Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer (NCT03984214) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2019-12-16 |
| Capsaicin to Prevent Delayed Chemotherapy Induced Nausea and Vomiting (CapCIN) (NCT04918069) | Christian Medical College, Vellore, India | 2019-10-18 |
| Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045) (NCT04054193) | Merck Sharp & Dohme LLC | 2019-09-09 |
| Prevention of Unmitigated Chemotherapy-induced Emesis (NCT03996863) | Otolith Labs | 2019-08-01 |
| Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer (NCT03571126) | Zunyi Medical College | 2019-05-09 |
| Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy (NCT04075955) | CR-CSSS Champlain-Charles-Le Moyne | 2019-04-29 |
| Adherence to the Antiemesis National Comprehensive Cancer Network (NCCN) Guideline (NCT03740672) | Lei Li | 2018-11-22 |
| Low Dose Aprepitant for Patients Receiving Carboplatin (NCT03237611) | Albert Einstein College of Medicine | 2018-10-30 |
| Observational Study on the Use of Akynzeo® in Patients Receiving HEC (NCT03649230) | Purdue Pharma, Canada | 2018-10-03 |
| the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy (NCT04430361) | Henan Cancer Hospital | 2018-09-07 |
| Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin (NCT03668639) | Christina Ruhlmann | 2018-09-05 |
| The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy (NCT03601871) | Yunpeng Liu | 2018-07-12 |
| A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer (NCT03403712) | Helsinn Healthcare SA | 2018-03-16 |
| Effect of tDCS of the Motor Cortex on Chemotherapy Induced Nausia and Vomiting (NCT03405324) | Shereen Mamdouh | 2018-01-01 |
| Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer (NCT02909478) | Sun Yat-sen University | 2017-09-01 |
| The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting (NCT03232541) | Västernorrland County Council, Sweden | 2017-09-01 |
| Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult Volunteers (NCT03245918) | The Hospital for Sick Children | 2017-08-10 |
| Community-Led Action Research in Oncology: Improving Symptom Management (NCT03208816) | Dartmouth-Hitchcock Medical Center | 2017-07-24 |
| "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)" (NCT03219710) | All India Institute of Medical Sciences | 2017-07-01 |
| The Comparative Study on the Efficacy and Safety of Single Acupoint and Matching Acupoints (NCT03061396) | Tianjin University of Traditional Chinese Medicine | 2017-02-17 |
| Dexamethasone-sparing Approach Including NEPA Against Emesis Caused by Cisplatin (NCT04201769) | Consorzio Oncotech | 2016-11-25 |
| Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (NCT02933099) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2016-10-01 |
| Promoting Cancer Symptom Management in Older Adults (NCT03143829) | University of Central Florida | 2016-08-11 |
| Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of CIN (NCT02970643) | Hee Jun Kim | 2016-07-01 |
| NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer (NCT03862144) | Consorzio Oncotech | 2016-05-12 |
| Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum (NCT05512676) | Oslo University Hospital | 2016-03-07 |
| Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy (NCT02445872) | Zhejiang University | 2015-12-01 |
| A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting (NCT02517021) | Helsinn Healthcare SA | 2015-11-01 |
| An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting (NCT02557035) | Helsinn Healthcare SA | 2015-10-01 |
| Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044) (NCT02519842) | Merck Sharp & Dohme LLC | 2015-09-14 |
| Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy (NCT03674294) | Sun Yat-sen University | 2015-08-04 |
| Comparative Effect Study Between Distal-proximal Point Association and Local Distribution Point Association in Chemotherapy-induced Nausea and Vomiting (NCT02478047) | Tianjin University of Traditional Chinese Medicine | 2015-06-01 |
| An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects (NCT02434861) | Tesaro, Inc. | 2015-05-01 |
| Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting (NCT02484911) | First Affiliated Hospital of Harbin Medical University | 2015-05-01 |
| Acupuncture for Chemotherapy-Induced Nausea and Vomiting (NCT02195921) | Tianjin University of Traditional Chinese Medicine | 2015-04-01 |
| Efficacy of Ginger as an Adjunctive Prophylaxis for Chemotherapy-induced Nausea and Vomiting (NCT02390648) | Mahidol University | 2015-03-01 |
| Acupuncture for Chemical Therapy Induced Nausea and Vomiting: a Cross-over Trail (NCT02127255) | Beijing University of Chinese Medicine | 2014-04-01 |
| A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC (NCT02106494) | Heron Therapeutics | 2014-03-01 |
| Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility Study (NCT02129478) | The Hospital for Sick Children | 2014-03-01 |
| Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy (NCT02097823) | Indiana University | 2014-02-01 |
| Evaluation of Predictive Risk Factors of Chemotherapy-induced Nausea and Vomiting (NCT01993381) | The Catholic University of Korea | 2013-11-01 |
| Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma (NCT01874119) | St. Louis University | 2013-09-01 |
| A Randomized Controlled Trial of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting (NCT01937156) | Solasia Pharma K.K. | 2013-08-01 |
| Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors (NCT01736917) | Lawrence Einhorn | 2013-01-01 |
| A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients (NCT01757210) | West Virginia University Healthcare | 2012-09-01 |
| Fosaprepitant in Patients Receiving Ifosfamide-based Regimen (NCT01490060) | M.D. Anderson Cancer Center | 2012-05-01 |
| Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years (NCT01596400) | Kyowa Kirin Pharmaceutical Development Ltd | 2012-05-01 |
| Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy (NCT01500226) | Tesaro, Inc. | 2012-02-01 |
| Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy (NCT01500213) | Tesaro, Inc. | 2012-02-01 |
| Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients (NCT01370408) | Northside Hospital, Inc. | 2012-02-01 |
| Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy (NCT01499849) | Tesaro, Inc. | 2012-02-01 |
| Efficacy and Safety Evaluation of Carbamazepine for Prevention of Chemotherapy-induced Nausea and Vomiting (NCT01581918) | Faculdade de Medicina do ABC | 2011-12-01 |
| Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic Patients (NCT02205164) | Associazione Salentina Angela Serra | 2011-10-01 |
| A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208) (NCT01362530) | Merck Sharp & Dohme LLC | 2011-09-13 |
| Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients (NCT01442376) | Helsinn Healthcare SA | 2011-09-01 |
| Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy (NCT01402024) | All India Institute of Medical Sciences | 2011-08-01 |
| A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting (NCT01376297) | Helsinn Healthcare SA | 2011-07-01 |
| Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting (NCT01481831) | Shanghai Changzheng Hospital | 2011-07-01 |
| An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting (NCT01363479) | Helsinn Healthcare SA | 2011-07-01 |
| Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy (NCT01346267) | University of South Florida | 2011-05-01 |
| An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting (NCT01339260) | Helsinn Healthcare SA | 2011-04-01 |
| Phase II Proof-of-concept Study of APD421 (NCT01303978) | Acacia Pharma Ltd | 2011-02-01 |
| Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin (NCT01012336) | Samsung Medical Center | 2010-05-01 |
| Effect of Yoga in Reducing Chemotherapy Induced Nausea and Vomiting (NCT01387841) | Bharath Charitable Cancer Hospital and Institute | 2010-05-01 |
| Acupuncture for Chemical Therapy Induced Nausea and Vomiting (NCT02842307) | Beijing University of Chinese Medicine | 2010-01-01 |
| A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy (NCT00891761) | GlaxoSmithKline | 2009-09-01 |
| A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134) (NCT00818259) | Merck Sharp & Dohme LLC | 2009-02-05 |
| A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165) (NCT00945321) | Merck Sharp & Dohme LLC | 2009-02-01 |
| Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting (NCT00787566) | Shin Nippon Biomedical Laboratories, Ltd. | 2008-10-01 |
| Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer (NCT00553059) | M.D. Anderson Cancer Center | 2008-05-01 |
| Re-examination Study of EMEND (Aprepitant) (MK-0869-184) (NCT01074255) | Merck Sharp & Dohme LLC | 2007-04-01 |
| Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED) (NCT00337727) | Merck Sharp & Dohme LLC | 2007-01-01 |
| Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic Chemotherapy (NCT00359567) | Taiho Pharmaceutical Co., Ltd. | 2006-07-01 |
| Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy (NCT01018758) | Gruppo Italiano Studio Linfomi | 2006-07-01 |
| To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV) (NCT00273468) | Kyowa Kirin Co., Ltd. | 2006-01-01 |
| Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting (NCT01031498) | M.D. Anderson Cancer Center | 2005-09-01 |
| A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012) (NCT00990821) | Merck Sharp & Dohme LLC | 2005-01-01 |
| Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy (NCT00104403) | GlaxoSmithKline | 2004-12-01 |
| Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041) (NCT00211601) | Merck Sharp & Dohme LLC | 2004-08-01 |
| Mindfulness Relaxation Compared With Relaxing Music and Standard Symptom Management Education in Treating Patients Who Are Undergoing Chemotherapy For Newly Diagnosed Solid Tumors (NCT00086762) | M.D. Anderson Cancer Center | 2004-06-01 |
| Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106) (NCT00972595) | Merck Sharp & Dohme LLC | 2004-06-01 |
| A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED) (NCT00971633) | Merck Sharp & Dohme LLC | 2003-11-01 |
| Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting (NCT00642512) | Solvay Pharmaceuticals | 2003-07-01 |
| An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients (NCT00666783) | Xijing Hospital | |
| Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years (NCT01596426) | Kyowa Kirin Pharmaceutical Development Ltd | |